PMC4554357_01
BCR-ABL levels during the course of treatment. BCR-ABL transcript levels were monitored by quantitative polymerase chain reaction either in the bone marrow (bm) or peripheral blood (pb) and expressed as the logarithmic ratio of BCR-ABL to the control gene ABL.
bmi-suppl.3-2015-025f1.jpg
PMC4554357_01_bmi-suppl.3-2015-025f1.jpg
f1-bmi-suppl.3-2015-025
CD19, and CD79a with notable absence of cytoplasmic CD22), myeloid (CD13, CD15, and CD33), and progenitor (CD34, TdT, and CD117) markers. Cytogenetic and molecular analyses of the bone marrow confirmed the presence of a translocation t(9;22)(q34;q11.2) and chimeric BCR-ABL mRNA transcripts (Fig. 1), thus establishing the diagnosis of CML in mixed phenotype blast crisis according to the revised criteria of the European Group for the Immunological Classification of Leukemias.